Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Thursday,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday.

Coya Therapeutics Trading Up 0.3 %

NASDAQ COYA opened at $6.47 on Thursday. The firm has a market capitalization of $108.09 million, a PE ratio of -9.95 and a beta of 0.31. The business’s 50-day moving average price is $6.31 and its two-hundred day moving average price is $6.48. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics during the 4th quarter valued at $401,000. CM Management LLC boosted its stake in Coya Therapeutics by 11.1% during the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after acquiring an additional 15,941 shares in the last quarter. Jane Street Group LLC acquired a new stake in Coya Therapeutics in the fourth quarter worth $74,000. Finally, Northern Trust Corp increased its stake in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.